News Novo Nordisk cuts Wegovy price ahead of TrumpRx launch Novo Nordisk has jumped the gun on US price reductions for its blockbuster diabetes and weight-loss drug semaglutide.
News Novo Nordisk fights back with oral GLP-1 data in obesity Shortly after reporting weaker sales growth for its injectable GLP-1 drugs, Novo Nordisk has new data to help it stake a claim to the oral market.
News Novo Nordisk cuts guidance again on weaker GLP-1 growth Novo Nordisk's first set of financial results under new CEO Mike Doustdar continues the theme of lower growth expectations for the company this year.
News Lilly says oral GLP-1 could be 'foundational' diabetes drug Eli Lilly has built the case for its oral GLP-1 orforglipron with two more phase 3 readouts, including a head-to-head win over Farxiga in diabetes.
News $600m round will help Kailera push obesity drug into phase 3 Kailera Therapeutics has raised an eye-watering $600 million in Series B financing to take its lead drug for weight loss into pivotal trials.
News GLP-1s from Novo, Lilly 'should be first-line in obesity' European doctors have said GLP-1 drugs are so effective in obesity that they should be the first choice drug treatment in almost all cases.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
